|
시장보고서
상품코드
2108991
중추신경계(CNS) 치료제 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Central Nervous System (CNS) Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 중추신경계(CNS) 치료제 시장은 2025년 1,386억 달러로 추산되며, 2034년까지 2,71억 달러에 달할 것으로 예측됩니다. 이러한 성장의 배경으로는 전 세계적으로 신경퇴행성 질환 및 정신 질환의 유병률이 증가하고 있는 점, 알츠하이머병 및 다발성 경화증에 대한 병태 수정형 바이오의약품 파이프라인이 급속히 확대되고 있는 점, 그리고 정신 질환의 진단 및 치료가 확대되고 있는 점을 들 수 있습니다.
- 전 세계 중추신경계(CNS) 치료제 시장은 2026년부터 2034년까지의 예측 기간 동안 연평균 성장률(CAGR) 8.5%로 성장하고 있습니다.
- 약제 모달리티별로는 2025년에 저분자 약물 부문이 64%의 점유율을 차지하며 중추신경계 치료제 시장을 주도했습니다.
- 약제 분류별로는 2025년에 항우울제 부문이 27%의 점유율을 차지하며 중추신경계 치료제 시장을 주도했습니다.
- 투여 경로별로는 2025년에 경구 투여 부문이 68%의 점유율을 차지하며 중추신경계 치료제 시장을 주도했습니다.
- 질환 유형별로는 2025년에 알츠하이머병 부문이 중추신경계 치료제 시장에서 31%의 점유율을 차지하며 시장을 주도했습니다.
- 북미는 2025년에 41.8%의 점유율을 차지하며 전 세계 CNS 치료제 시장의 매출을 견인했고, 지역별로는 전 세계에서 가장 높은 시장 점유율을 기록했습니다.
중추신경계(CNS) 치료제란 신경퇴행성 질환, 정신 질환, 간질, 탈수초성 질환 등 뇌와 척수에 영향을 미치는 질환의 진단, 관리, 치료에 사용되는 의약품 및 치료법을 의미합니다. 혈뇌장벽이 약물의 침투를 제한하고, 또한 CNS 질환의 경우 대개 면밀한 모니터링을 동반한 장기적인 치료가 필요하기 때문에 이 시장은 광범위한 약물 모달리티와 치료 환경을 아우르고 있습니다. 이 시장은 약물 모달리티별(저분자 화합물, 단일클론 항체, 펩타이드, 기타), 약물 분류별(항우울제, 항정신병제, 항간질약, 면역조절제 등), 투여 경로별(경구, 정맥 내, 피하 투여), 질환 유형별(알츠하이머병, 파킨슨병, 간질, 다발성 경화증이 주요), 그리고 최종 사용자별(병원, 신경과 클리닉)로 분류됩니다. 세계적인 고령화, 질환 수정형 생물학적 제제의 파이프라인 확대, 그리고 정신 질환에 대한 인식 제고와 진단 건수 증가에 힘입어, 중추신경계 치료제는 전 세계 의약품 연구 및 상용화 분야에서 가장 규모가 크고 주목받는 카테고리 중 하나가 되었습니다.
중추신경계 치료제 시장의 주요 성장 촉진요인
- 신경퇴행성 질환 및 정신 질환의 전 세계적 부담 증가가 수요를 견인하고 있으며, 세계보건기구(WHO)의 추정에 따르면 전 세계적으로 5,500만 명 이상이 치매를 앓고 있으며, 수억 명이 우울증, 불안 장애 및 기타 정신 질환의 영향을 받고 있는 것으로 알려져 있습니다.
- 알츠하이머병에 대한 질병 수정 요법의 임상 및 상업적 측면에서의 급속한 확대로 인해 대상 시장이 확대되고 있으며, 레켄비(Lekenbi)나 키슨라(Kisunla)와 같은 항아밀로이드 항체가 더 광범위한 규제 당국의 승인 및 보험 적용 범위를 확보하고 있습니다.
- 노바티스의 케신프타와 같은 고효능 약물을 포함한 다발성 경화증에 대한 면역 조절 생물학적 제제의 채택이 확대됨에 따라, 질환 수정 요법 부문이 성장하고 있습니다.
- 낙인 경감 및 의료 접근성 확대에 힘입어 정신 질환의 진단과 치료가 증가하고 있어, 항우울제, 항정신병제 및 차세대 정신과 치료제에 대한 수요가 확대되고 있습니다.
- 뇌 셔틀 항체 기술 및 신규 펩타이드 플랫폼 등 혈액-뇌 장벽 투과형 약물 전달 기술의 발전으로 효능이 향상되어, 신경퇴행성 질환을 대상으로 한 개발 파이프라인이 확대되고 있습니다.
- 전 세계 인구의 고령화가 급속히 진행됨에 따라 알츠하이머병, 파킨슨병 및 기타 노화 관련 신경 질환의 발병률이 직접적으로 증가하고 있습니다.
- 대규모 인수합병 및 라이선싱 계약에서 드러나듯이, 신경과학에 대한 투자자와 대형 제약사의 강한 관심으로 인해 중추신경계(CNS) 치료제 파이프라인 개발 및 신제품 시장 출시가 가속화되고 있습니다.
- 고령화, 생물학적 제제의 혁신, 그리고 정신 질환 치료율의 상승이 맞물려, 2034년까지 이 시장은 높은 한 자릿수 후반대의 성장률을 유지할 것으로 예측됩니다.
중추신경계 치료제 시장의 성장에 기여하는 요인
시장 성장 촉진요인
신경퇴행성 질환 및 정신 질환 유병률 증가
중추신경계 치료제 시장의 가장 강력한 촉진요인은 근본적인 질환 부담의 규모와 그 증가입니다. 알츠하이머병, 파킨슨병, 간질, 다발성 경화증, 우울증, 조현병은 전 세계적으로 합쳐서 수억 명에게 영향을 미치고 있으며, 인구 고령화와 진단 인식의 향상에 따라 유병률은 계속 상승하고 있습니다. 우울증과 불안 장애만으로도 전 세계 질병 부담의 상당 부분을 차지하고 있으며, 치매 환자 수는 2050년까지 약 3배로 증가할 것으로 예측됩니다. 중추신경계 질환의 대부분은 만성적이고 종종 평생에 걸친 약물 치료가 필요하기 때문에 진단 건수가 1건 증가할 때마다 지속적이고 반복적인 치료 수요로 이어집니다. 선별 검사 프로그램의 확대와 임상의에 의한 질환 조기 발견이 진전됨에 따라, 치료 대상이 되는 환자 수는 단순한 유병률 수치가 시사하는 것보다 빠른 속도로 증가하고 있으며, 이것이 2034년까지 지속될 시장 성장의 기반이 되고 있습니다.
알츠하이머병 병태 수정 요법 분야의 파이프라인 확대 및 승인 진전
새로 승인된 항아밀로이드 항체와 개발 중인 항아밀로이드 항체의 물결이 알츠하이머병 치료 방식을 혁신적으로 변화시키며 시장 상황을 확대되고 있습니다. Eli Lilly의 키슨라(도나네맙) 및 Biogen과 Eisai의 레켄비(레카네맙)는 주요 시장에서 승인을 획득했으며, 레켄비의 피하 투여용 유지 요법 제제는 2025년 초 FDA 승인을 받아, 편의성이 향상되어 더욱 광범위한 보급이 촉진되고 있습니다. 로슈(Roche)는 혈액-뇌 장벽 투과성을 높이기 위해 설계되어 뇌로 전달이 가능한 항아밀로이드 후보 약물 트로니테맙에 대해 후기 임상 개발을 지속적으로 진행하고 있습니다. 혈액 기반 바이오마커 검사를 포함한 진단 인프라가 확대되고, 환자 선별 및 보험 급여 체계가 성숙해짐에 따라, 알츠하이머병의 병태 수정 요법은 예측 기간 동안 중추신경계(CNS) 치료제 전체 매출에서 주요하고 급성장하는 요인이 될 것으로 기대됩니다.
시장 제약 요인
강력한 성장세를 보이고 있음에도 불구하고, 중추신경계 치료제 시장은 중대한 제약에 직면해 있습니다. 혈액-뇌 장벽은 여전히 근본적인 장벽으로 작용하여, 전신 투여된 약물 중 뇌 조직에서 치료 농도에 도달하는 비율을 제한할 뿐만 아니라, 다른 중추신경계 치료 분야와 비교했을 때 임상 개발에서 높은 실패율의 원인이 되고 있습니다. 알츠하이머병 병태 수정 항체에는 아밀로이드 관련 영상 이상 등 안전성상의 우려가 있으며, 집중적인 MRI 모니터링과 전문적인 인프라가 필요하기 때문에 주요 학술 기관이나 병원 이외의 곳에서는 도입이 제한되고 있습니다. 신규 생물학적 제제나 면역 조절제의 고액 치료비는 특히 가격에 민감한 시장이나 신흥 시장에서 보험 환급과 관련된 마찰을 야기하고 있습니다. 한편, 이미 확립된 저분자 항우울제 및 항간질제는 제네릭 의약품과 바이오시밀러에 의한 지속적인 시장 잠식에 직면해 있어, 브랜드 의약품의 매출에 압박을 가하고 있습니다. 임상 개발의 장기화, 높은 시험 실패율, 그리고 진행 속도가 느린 신경퇴행성 질환에 대해 민감한 평가 지표를 설계하기의 어려움은 연구 개발 비용을 상승시키고 신제품 출시를 지연시키고 있습니다. 많은 지역에서 훈련을 받은 신경과 전문의나 정신과 전문의가 부족하여 진단 및 치료 능력이 제한되고 있으며, 정신 질환에 대한 진단적 편견과 사회적 편견이 일부 지역에서 여전히 치료를 받는 것을 방해하고 있습니다. 이러한 임상적, 규제적, 비용적, 그리고 인력 측면의 장벽이 복합적으로 작용함에 따라, 인구 고령화, 생물학적 제제의 혁신, 정신 건강 치료의 확대와 같은 근본적인 촉진요인이 여전히 확고하게 존재함에도 불구하고 성장 속도는 둔화되고 있습니다.
자주 묻는 질문
목차
제1장 중추신경계 치료제 시장 보고서 서론
제2장 중추신경계 치료제 시장 주요 요약
제3장 중추신경계 치료제 시장의 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter의 Five Forces 분석
제7장 중추신경계 치료제 시장 평가
제8장 중추신경계 치료제 시장 경쟁 구도
제9장 중추신경계 치료제 시장 스타트업의 자금조달 및 투자 동향
제10장 중추신경계 치료제 시장 : 기업 개요 및 제품 개요
제10장 H. Lundbeck A/S
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSH 26.08.13Central Nervous System Therapeutics Market Summary
Overview:
- The Central Nervous System (CNS) Therapeutics market is estimated at USD 138.60 billion in 2025 and is projected to reach USD 271.30 billion by 2034. Growth is anchored in the rising global prevalence of neurodegenerative and psychiatric disorders, the rapid expansion of the disease-modifying Alzheimer's and multiple sclerosis biologics pipeline, and growing diagnosis and treatment of mental health conditions.
- The global CNS Therapeutics market is growing at a CAGR of 8.5% during the forecast period from 2026 to 2034.
- By drug modality, the small molecules segment dominated the CNS Therapeutics market with a 64% share in 2025.
- By drug class, the antidepressants segment dominated the CNS Therapeutics market with a 27% share in 2025.
- By route of administration, the oral segment dominated the CNS Therapeutics market with a 68% share in 2025.
- By disease type, the Alzheimer's disease segment dominated the CNS Therapeutics market with a 31% share in 2025.
- North America dominated the global CNS Therapeutics market revenue with a 41.8% share in 2025, representing the highest regional market share globally.
Central Nervous System (CNS) therapeutics comprise the pharmaceutical products and treatment modalities used to diagnose, manage, and treat disorders affecting the brain and spinal cord, including neurodegenerative diseases, psychiatric disorders, epilepsy, and demyelinating conditions. Because the blood-brain barrier restricts drug penetration and CNS disorders often require chronic, closely monitored therapy, the market spans a broad range of drug modalities and treatment settings. The market is organized by drug modality across small molecules, monoclonal antibodies, peptides, and others; by drug class, including antidepressants, antipsychotics, antiepileptic drugs, and immunomodulators; by route of administration across oral, intravenous, and subcutaneous delivery; by disease type, led by Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis; and by end-user across hospitals and neurology clinics. Driven by an aging global population, an expanding pipeline of disease-modifying biologics, and rising awareness and diagnosis of mental health conditions, CNS therapeutics have become one of the largest and most closely watched categories in global pharmaceutical research and commercialization.
Central Nervous System Therapeutics Market Key Growth Drivers
- The rising global burden of neurodegenerative and psychiatric disorders is driving demand, with the World Health Organization estimating that more than 55 million people live with dementia worldwide and hundreds of millions more affected by depression, anxiety, and other mental health conditions.
- The rapid clinical and commercial expansion of disease-modifying Alzheimer's therapies is expanding the addressable market, with anti-amyloid antibodies such as Leqembi and Kisunla gaining broader regulatory approvals and reimbursement coverage.
- Growing adoption of immunomodulatory biologics for multiple sclerosis, including high-efficacy agents such as Novartis' Kesimpta, is expanding the disease-modifying therapy segment.
- Increasing diagnosis and treatment of mental health disorders, supported by reduced stigma and expanding access to care, is broadening demand for antidepressants, antipsychotics, and next-generation psychiatric therapies.
- Advances in blood-brain-barrier-penetrant drug delivery, including brain-shuttle antibody technology and novel peptide platforms, are improving efficacy and expanding the addressable pipeline for neurodegenerative disease.
- A rapidly aging global population is directly increasing the incidence of Alzheimer's disease, Parkinson's disease, and other age-related neurological disorders.
- Strong investor and big-pharma interest in neuroscience, evidenced by large-scale acquisitions and licensing deals, is accelerating pipeline development and commercial launch of new CNS therapeutics.
- The convergence of an aging population, biologics innovation, and rising mental health treatment rates is expected to sustain strong high-single-digit growth in the market through 2034.
Key Companies in Central Nervous System Therapeutics Market
The competitive landscape is led by the following active manufacturers:
- Biogen
- Eli Lilly and Company
- Roche
- Novartis
- AbbVie
- Bristol Myers Squibb
- Johnson & Johnson
- Pfizer
- Otsuka Pharmaceutical
- Lundbeck
Factors Contributing to the Growth of the Central Nervous System Therapeutics Market
Market Drivers
Rising Prevalence of Neurodegenerative and Psychiatric Disorders
The most powerful driver of the CNS Therapeutics market is the sheer scale and growth of the underlying disease burden. Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, depression, and schizophrenia collectively affect hundreds of millions of people worldwide, and prevalence continues to climb as populations age and diagnostic awareness improves. Depression and anxiety disorders alone account for a substantial share of the global disease burden, while dementia cases are projected to nearly triple by 2050. Because most CNS disorders require chronic, often lifelong pharmacological management, each incremental diagnosis translates into sustained, recurring therapeutic demand. As screening programs expand and clinicians identify disease earlier in its course, the treated population grows faster than raw prevalence alone would suggest, anchoring durable market growth through 2034.
Expanding Pipeline and Approvals of Disease-Modifying Alzheimer's Therapies
A wave of newly approved and pipeline anti-amyloid antibodies is reshaping the Alzheimer's treatment landscape and expanding the addressable market. Eli Lilly's Kisunla (donanemab) and Biogen and Eisai's Leqembi (lecanemab) have secured approvals across major markets, and Leqembi's subcutaneous maintenance-dosing formulation received FDA approval in early 2025, improving convenience and supporting broader adoption. Roche continues to advance trontinemab, a brain-shuttle-enabled anti-amyloid candidate designed to improve blood-brain-barrier penetration, through late-stage clinical development. As diagnostic infrastructure, including blood-based biomarker tests, expands patient identification and reimbursement pathways mature, disease-modifying Alzheimer's therapies are expected to become a major and fast-growing contributor to overall CNS therapeutics revenue through the forecast period.
Market Restraints
Despite strong momentum, the CNS Therapeutics market faces material constraints. The blood-brain barrier remains a fundamental obstacle, limiting the proportion of systemically administered drugs that reach therapeutic concentrations in brain tissue and driving high attrition rates in CNS clinical development relative to other therapeutic areas. Disease-modifying Alzheimer's antibodies carry safety considerations, including amyloid-related imaging abnormalities, that require intensive MRI monitoring and specialist infrastructure, constraining uptake outside major academic and hospital centers. High treatment costs for novel biologics and immunomodulators create reimbursement friction, particularly in price-sensitive and emerging markets, while established small-molecule antidepressants and antiepileptic drugs face sustained generic and biosimilar erosion that pressures branded revenue. Long clinical development timelines, high trial failure rates, and the difficulty of designing sensitive endpoints for slowly progressing neurodegenerative disease raise R&D costs and delay new product launches. A shortage of trained neurologists and psychiatrists in many regions constrains diagnosis and treatment capacity, and diagnostic and social stigma around mental illness continues to limit treatment-seeking in several geographies. Together, these clinical, regulatory, cost, and workforce barriers temper the pace of growth, even as the underlying drivers of demographic aging, biologics innovation, and expanding mental health treatment remain firmly intact.
Central Nervous System Therapeutics Market Segment Analysis
The Central Nervous System Therapeutics Market by Drug Modality (Small Molecules, Monoclonal Antibodies, Peptides, and Others), Drug Class (Antidepressants, Antipsychotics, Antiepileptic Drugs, Immunomodulators, and Others), Route of Administration (Oral, Intravenous (IV), Subcutaneous, and Others), Disease Type (Alzheimer's Disease, Parkinson's Disease, Epilepsy, Multiple Sclerosis, and Others), End-Users (Hospitals, Neurology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).
By Drug Modality
Dominant Subsegment: Small Molecules.
Small molecules are the leading drug modality because they underpin the largest and most established treatment categories in CNS care, including antidepressants, antipsychotics, and antiepileptic drugs, most of which are oral, low-cost, and administered by primary-care physicians and psychiatrists across both developed and emerging markets. Decades of clinical use, well-characterized safety profiles, and broad generic availability sustain very high prescription volumes across depression, anxiety, schizophrenia, and epilepsy. While monoclonal antibodies are the fastest-growing modality, propelled by disease-modifying Alzheimer's and multiple sclerosis therapies such as Leqembi, Kisunla, and Kesimpta, the sheer breadth, affordability, and prescribing familiarity of small-molecule therapeutics secure the segment's leadership across the forecast period.
By Drug Class
Dominant Subsegment: antidepressants.
Antidepressants are the leading drug class because major depressive disorder and anxiety-related conditions represent the highest-prevalence psychiatric diagnoses worldwide, and treatment is typically chronic, spanning months to years per patient. Reduced stigma, expanded telehealth-enabled prescribing, and growing primary-care screening continue to widen the diagnosed and treated population. Antipsychotics form a large and growing second category, reinforced by differentiated recent launches including Bristol Myers Squibb's Cobenfy and Otsuka and Lundbeck's Rexulti, while antiepileptic drugs remain essential to a large, stable epilepsy population. Immunomodulators are the fastest-growing class, driven by high-efficacy multiple sclerosis and emerging Alzheimer's biologics, but the scale and chronicity of antidepressant use secure that segment's leadership across the forecast period.
Central Nervous System Therapeutics Market Region Analysis
Dominant Region: North America
North America accounted for 41.8 % of the global central nervous system therapeutics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature neurology and psychiatry treatment infrastructure, high diagnosis rates, favorable reimbursement for novel biologics, and the concentration of leading innovators, including Biogen, Eli Lilly, AbbVie, Bristol Myers Squibb, and Johnson & Johnson, headquartered or heavily commercially active in the United States. North America was the first region to secure regulatory approval and broad reimbursement for disease-modifying Alzheimer's antibodies such as Leqembi and Kisunla, and it hosts the largest concentration of specialized infusion and imaging infrastructure required for their administration. Strong FDA regulatory clarity, an active late-stage clinical pipeline, and sustained M&A activity, including AbbVie's Cerevel acquisition and Johnson & Johnson's Intra-Cellular Therapies acquisition, further anchor the region's leadership. High diagnosis rates for depression, anxiety, and other psychiatric conditions, combined with broad commercial insurance coverage, sustain the region's continued dominance across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Central Nervous System Therapeutics market. The region's elevated CAGR is driven by rapidly aging populations in Japan, China, and South Korea, expanding healthcare investment, and rising diagnosis rates for both neurodegenerative and psychiatric disorders. Japan is an early adopter of novel Alzheimer's therapies and maintains an advanced neurology infrastructure; China is expanding dementia-care capacity and mental-health treatment access amid a fast-growing geriatric population, and India is broadening access to affordable generic antidepressants and antiepileptic drugs across a large, underserved patient population. Government healthcare investment, growing private insurance penetration, and expanding clinical-trial activity from global CNS innovators are accelerating regional adoption of both established and novel therapies. The combination of demographic aging, rising disease awareness, and healthcare infrastructure build-out positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 41.8% of the global CNS Therapeutics market revenue in 2025. The United States dominates on the strength of its mature neurology and psychiatry care infrastructure, favorable reimbursement for novel biologics, FDA regulatory clarity, and the concentration of leading CNS innovators, while continued M&A activity and rapid uptake of disease-modifying Alzheimer's therapies reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by established EMA regulatory frameworks, strong public healthcare systems, and a deep base of neurology and psychiatry expertise across Germany, France, the United Kingdom, Italy, and Spain. Growing adoption of high-efficacy multiple sclerosis immunomodulators and expanding, though more cautious, reimbursement pathways for disease-modifying Alzheimer's antibodies reinforce the region's role as a major market for both established and novel CNS therapeutics.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rapidly aging populations, expanding healthcare investment, and rising diagnosis and treatment rates for neurodegenerative and psychiatric disorders across China, Japan, India, South Korea, and Australia. Japan's early adoption of novel Alzheimer's therapies, China's expanding dementia and mental-health infrastructure, and India's broadening access to affordable CNS medicines are accelerating regional market growth.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare infrastructure, rising awareness and diagnosis of psychiatric and neurodegenerative disorders, and gradually improving access to essential CNS medicines are broadening the treated population, while international partnerships and public health investment support the gradual build-out of specialized neurology and psychiatric care capacity.
Central Nervous System Therapeutics Market Competitive Landscape
The CNS Therapeutics market is classified as Moderately Concentrated. A group of large, diversified innovators with broad neuroscience portfolios, including Biogen, Eli Lilly and Company, Roche, and Novartis, anchor the top tier through disease-modifying Alzheimer's and multiple sclerosis franchises, while AbbVie, Bristol Myers Squibb, and Johnson & Johnson have rapidly built competitive psychiatric and neurodegenerative pipelines through large-scale acquisitions, and Pfizer, Otsuka Pharmaceutical, and Lundbeck compete through established antidepressant, antipsychotic, and migraine portfolios.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately concentrated, with diversified neuroscience leaders anchoring the top tier and a fast-moving field of acquisition-driven challengers in psychiatry and neurodegeneration.
- Leading players: Biogen, Eli Lilly and Company, Roche, and Novartis anchor the top tier through disease-modifying Alzheimer's and multiple sclerosis franchises.
- Geographic reach: Leaders operate global commercial networks spanning North America, Europe, and Asia-Pacific, essential for coordinating specialist prescribing, infusion infrastructure, and biomarker-based diagnostics.
- Portfolio strength: Top players offer broad neuroscience portfolios spanning small-molecule, monoclonal antibody, and peptide therapeutics across neurodegenerative, psychiatric, and demyelinating disease.
- Pipeline depth: Late-stage disease-modifying candidates, including brain-shuttle antibodies and novel antipsychotic mechanisms, are a decisive competitive advantage.
- Strategic partnerships: Co-promotion agreements, such as Otsuka and Lundbeck's partnership on Rexulti, extend commercial reach and shared development risk.
- M&A activity: Active consolidation, including AbbVie's acquisitions of Cerevel Therapeutics and Aliada Therapeutics, Bristol Myers Squibb's acquisition of Karuna Therapeutics, and Johnson & Johnson's acquisition of Intra-Cellular Therapies.
- Manufacturing and delivery capabilities: Specialized biologics manufacturing, blood-brain-barrier-penetrant delivery technology, and self-administration device development are key competitive moats.
- Innovation focus: Anti-amyloid and anti-tau biologics, high-efficacy immunomodulators, novel antipsychotic mechanisms, and blood-brain-barrier delivery platforms.
Central Nervous System Therapeutics Market Recent Developmental Activities
July, 2024: Biogen and Eisai announced that the European Commission granted marketing authorization for Leqembi(R) (lecanemab) for the treatment of early Alzheimer's disease in eligible patients, expanding access to disease-modifying therapy in Europe.
July, 2024: Eli Lilly and Company received U.S. FDA approval for Kisunla(R) (donanemab) for adults with early symptomatic Alzheimer's disease, making it another approved anti-amyloid therapy for slowing disease progression.
Central Nervous System Therapeutics Market Segmentation
Central Nervous System Therapeutics Market by Drug Modality
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Others
Central Nervous System Therapeutics Market by Drug Class
- Antidepressants
- Antipsychotics
- Antiepileptic Drugs
- Immunomodulators
- Others
Central Nervous System Therapeutics Market by Route of Administration
- Oral
- Intravenous (IV)
- Subcutaneous
- Others
Central Nervous System Therapeutics Market by Disease Type
- Alzheimer's Disease
- Parkinson's Disease
- Epilepsy
- Multiple Sclerosis
- Others
Central Nervous System Therapeutics Market by End-Users
- Hospitals
- Neurologic Clinics
- Others
Central Nervous System Therapeutics Market by Geography
- North America Central Nervous System Therapeutics Market
- United States Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Canada Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Mexico Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Europe Central Nervous System Therapeutics Market
- Germany Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- United Kingdom Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- France Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Italy Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Spain Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Rest of Europe Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Asia-Pacific Central Nervous System Therapeutics Market
- China Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Japan Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- India Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Australia Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- South Korea Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Rest of the World (RoW) Central Nervous System Therapeutics Market
- Middle East Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- Africa Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- South America Central Nervous System Therapeutics Market Size in USD million (2023-2034)
Key Takeaways from the Central Nervous System Therapeutics Market Report Study
- Market size analysis for the current central nervous system therapeutics market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global central nervous system therapeutics market.
- Various opportunities available for competitors in the central nervous system therapeutics market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current central nervous system therapeutics market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for central nervous system therapeutics market growth in the future?
Target audience who can benefit from this central nervous system therapeutics market report study
- Central nervous system therapeutics product providers
- Research organizations and consulting companies
- Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in central nervous system therapeutics
- Various end-users who want to know more about the central nervous system therapeutics market and the latest technological developments in the central nervous system Therapeutics market.
Frequently Asked Questions:
Q1. What is the growth rate of the Central Nervous System Therapeutics market?
The Central Nervous System Therapeutics market is projected to expand at a CAGR of 8.5% during the forecast period from 2026-2034.
Q2. What is the market size of the Central Nervous System Therapeutics market?
The Central Nervous System Therapeutics market is estimated at USD 138.60 billion in 2025 and is projected to reach SD 271.30 billion by 2034.
Q3. Which region dominates the Central Nervous System Therapeutics market?
North America dominated the CNS Therapeutics market with a 41.8% share of global revenue in 2025, supported by a mature neurology and psychiatry treatment infrastructure, favorable reimbursement for novel biologics, FDA regulatory clarity, and the concentration of leading neuroscience innovators. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Central Nervous System Therapeutics market?
The principal drivers are the rising global prevalence of neurodegenerative and psychiatric disorders; the rapid clinical and commercial expansion of disease-modifying Alzheimer's therapies such as Leqembi and Kisunla; growing adoption of high-efficacy immunomodulators for multiple sclerosis; increasing diagnosis and treatment of mental health disorders; advances in blood-brain-barrier-penetrant drug delivery; and a rapidly aging global population.
Q5. Who are the major players in the Central Nervous System Therapeutics market?
The major players include Biogen, Eli Lilly and Company, Roche, Novartis, AbbVie, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Otsuka Pharmaceutical, and Lundbeck, among other active innovators profiled in the Competitive Landscape section. Biogen, Eli Lilly and Company, Roche, and Novartis lead through disease-modifying Alzheimer's and multiple sclerosis franchises.
Table of Contents
1. Central Nervous System Therapeutics Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Central Nervous System Therapeutics Market Executive Summary
- 2.1 Market at a Glance
3. Central Nervous System Therapeutics Market Key Factors Analysis
- 3.1 Central Nervous System Therapeutics Market Drivers
- 3.1.1 Rising Prevalence of Neurodegenerative and Psychiatric Disorders
- 3.1.2 Expansion of Disease-Modifying Alzheimer's Therapies
- 3.1.3 Growing Adoption of Multiple Sclerosis Immunomodulators
- 3.1.4 Increasing Diagnosis and Treatment of Mental Health Disorders
- 3.2 Central Nervous System Therapeutics Market Restraints and Challenges
- 3.2.1 Blood-Brain-Barrier Delivery Constraints
- 3.2.2 High Treatment Cost and Reimbursement Friction
- 3.2.3 Regulatory, Safety, and Workforce Complexity
- 3.3 Central Nervous System Therapeutics Market Opportunities
- 3.3.1 Blood-Brain-Barrier Delivery Innovation
- 3.3.2 Emerging-Market Access Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Central Nervous System Therapeutics Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Central Nervous System Therapeutics Market Assessment
- 7.1 By Drug Modality
- 7.1.1 Small Molecules
- 7.1.2 Monoclonal Antibodies
- 7.1.3 Peptides
- 7.1.4 Others
- 7.2 By Drug Class
- 7.2.1 Antidepressants
- 7.2.2 Antipsychotics
- 7.2.3 Antiepileptic Drugs
- 7.2.4 Immunomodulators
- 7.2.5 Others
- 7.3 By Route of Administration
- 7.3.1 Oral
- 7.3.2 Intravenous (IV)
- 7.3.3 Subcutaneous
- 7.3.4 Others
- 7.4 By Disease Type
- 7.4.1 Alzheimer's Disease
- 7.4.2 Parkinson's Disease
- 7.4.3 Epilepsy
- 7.4.4 Multiple Sclerosis
- 7.4.5 Others
- 7.5 By End-Users
- 7.5.1 Hospitals
- 7.5.2 Neurologic Clinics
- 7.5.3 Others
- 7.6 By Geography
- 7.6.1 North America
- 7.6.1.1 United States Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.1.2 Canada Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.1.3 Mexico Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.2 Europe
- 7.6.2.1 Germany Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.2 United Kingdom Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.3 France Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.4 Italy Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.5 Spain Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.6 Rest of Europe Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
- 7.6.3.1 China Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.2 Japan Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.3 India Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.4 Australia Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.5 South Korea Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.6 Rest of Asia-Pacific Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.4 Rest of World
- 7.6.4.1 Middle East Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.4.2 Africa Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.4.3 South America Central Nervous System Therapeutics Market Size in USD million (2023-2034)
- 7.6.1 North America
8. Central Nervous System Therapeutics Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Central Nervous System Therapeutics Market Startup Funding and Investment Trends
10. Central Nervous System Therapeutics Market Company and Product Profiles
- 10.1 Biogen Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Eli Lilly and Company
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Roche
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Novartis AG
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 AbbVie
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Bristol Myers Squibb
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Johnson & Johnson
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Pfizer
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Otsuka Pharmaceutical
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10. H. Lundbeck A/S
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
